首页> 外文期刊>Vaccine >Neutralizing antibody response after intradermal rabies vaccination in hemodialysis patients
【24h】

Neutralizing antibody response after intradermal rabies vaccination in hemodialysis patients

机译:血液透析患者皮内狂犬病疫苗接种后的中和抗体反应

获取原文
获取原文并翻译 | 示例
           

摘要

Abnormal immune function in chronic hemodialysis (HD) patients could impair immunologic responsiveness to various vaccinations. Such inadequate response makes the HD patients to be at risk of certain fatal but preventable diseases including rabies. Although the effectiveness of rabies vaccination has been established in healthy subjects, the responsiveness of the current rabies vaccination has never been examined in HD patients. The effectiveness of post-exposure rabies vaccine was assessed in 20 stable thrice-a-week chronic HD patients who received adequate dialysis and did not have history of rabies vaccination during the last 20 years. All participants received the standard intradermal Thai Red Cross post-exposure rabies vaccination. Blood samples were obtained for determination of rabies neutralizing antibody (Nab) before the first dose (day 0) and on days 14 and 90 after vaccination. Prior to simulated vaccination, six of twenty patients already had Nab titers above the protective levels of 0.5 IU/mL while the remaining fourteen patients showed undetectable Nab. All subjects reached Nab titers above 0.5 IU/mL(acceptable level for rabies protection) by days 14 after vaccination. The geometric mean titers (GMTs) on days 14 after vaccination were 3.2 + 3.1 IU/mL (range 0.81-9.17 IU/mL). At day 90 after vaccination, 13 of 14 patients had Nab titers above the protective levels, resulting in the response rate of 92.8%. The GMTs of Nab on day 90 after vaccination were 5.09 + 1.79 IU/mL (0.42-25.0 IU/mL). There were no correlations between Nab titers and patient characteristics. No serious adverse reactions were detected. In conclusion, chronic HD patients receiving adequate dialysis have excellent protective immunological response after intradermal post-exposure rabies vaccination as WHO recommendation.
机译:慢性血液透析(HD)患者的免疫功能异常可能会损害对各种疫苗的免疫反应。这种不足的反应使HD患者处于某些致命但可以预防的疾病中,包括狂犬病。尽管狂犬病疫苗接种的有效性已在健康受试者中确定,但目前尚未在HD患者中检查当前狂犬病疫苗接种的反应性。在20名稳定的每周进行三次透析的慢性HD患者中评估了暴露后的狂犬病疫苗的有效性,这些患者在过去的20年中接受了充分的透析并且没有狂犬病疫苗接种史。所有参与者均接受了标准的皮内泰国红十字会暴露后狂犬病疫苗接种。在首次剂量之前(第0天)以及疫苗接种后第14天和第90天,获取血样以测定狂犬病中和抗体(Nab)。在进行模拟疫苗接种之前,二十名患者中有六名已经具有高于保护水平0.5 IU / mL的Nab滴度,而其余十四名患者则显示出不可检测的Nab。接种后第14天,所有受试者的Nab滴度均达到0.5 IU / mL(狂犬病保护的可接受水平)以上。接种后第14天的几何平均滴度(GMT)为3.2 + 3.1 IU / mL(范围0.81-9.17 IU / mL)。接种疫苗后第90天,14例患者中有13例的Nab滴度高于保护水平,结果有效率92.8%。疫苗接种后第90天,Nab的GMT为5.09 + 1.79 IU / mL(0.42-25.0 IU / mL)。 Nab滴度与患者特征之间无相关性。没有发现严重的不良反应。总之,按照WHO的建议,在接受暴露后狂犬病皮内接种后,接受充分透析的慢性HD患者具有出色的保护性免疫学反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号